Prophase Labs Inc Stock Price, News & Analysis

ProPhase Labs (Nasdaq: PRPH) has announced that Chairman and CEO Ted Karkus will present at two upcoming investor conferences. He is set to deliver a corporate presentation at the Q3 Investor Summit on August 17, 2021, at 11:00 am ET. Additionally, he will present at the SNN Network Summer Virtual Event on August 18, 2021, at 2:00 pm ET. Management will be available for one-on-one meetings throughout both events. ProPhase Labs focuses on genomics testing and provides COVID-19 testing services.

ProPhase Labs, Inc. (NASDAQ: PRPH) reported a significant financial turnaround for Q2 2021. Total revenue surged to $9.1 million, up 153% from $3.6 million in Q2 2020. However, the company reported a net loss of $1.4 million, equating to $(0.09) per share, reversing from a net income of $70,000 in the prior year. The acquisition of Nebula Genomics is expected to expand its service offerings, and the firm maintained a strong cash position of $35.8 million post-dividend.

ProPhase Labs (Nasdaq: PRPH) has acquired Nebula Genomics for approximately $14.6 million, using a combination of cash and stock. This acquisition aims to merge Nebula's whole genome sequencing services with ProPhase's diagnostic testing, enhancing their offerings in personalized medicine. George Church, the founder of Nebula, will lead ProPhase's new Scientific Advisory Board. The move is expected to make genome sequencing more accessible and cost-effective, while leveraging ProPhase's existing retail network to expand its reach.

ProPhase Labs, Inc. (NASDAQ: PRPH) will hold a conference call on August 13, 2021 at 11:00 a.m. ET to discuss its Q2 2021 results. CEO Ted Karkus will lead the call, which includes a question-and-answer session. Participants can register online and will receive dial-in details upon registration. Those without internet access can join via toll-free and international phone numbers. The call will be streamed live and available for replay shortly after.

ProPhase Labs provides a range of clinical diagnostics and testing services, including COVID-19 testing with results in under 24 hours.

ProPhase Labs (Nasdaq: PRPH) announced that CEO Ted Karkus will present a corporate overview during the Access to Giving Virtual Investor Conference from July 13-15, 2021. Karkus's presentation is scheduled for July 15 at 9:30 AM ET, with management available for one-on-one meetings throughout the event. ProPhase Labs specializes in medical science and technology, including diagnostic testing for COVID-19 and other respiratory illnesses, with results provided in under 24 hours. For more details, visit www.ProPhaseLabs.com.

ProPhase Labs (Nasdaq: PRPH) has engaged CORE IR for investor relations and public relations support to enhance market awareness and communicate its business model effectively. CORE IR aims to expand ProPhase's institutional and retail investor base through its strategic advisory services. CEO Ted Karkus emphasized the company's unique growth story and diversification strategy. The partnership is expected to facilitate greater outreach and engagement with investors, aligning with ProPhase's objectives in the medical science and technology sector.

ProPhase Labs, Inc. (Nasdaq: PRPH) has been added to the Russell Microcap Index as of June 28, 2021, following the annual reconstitution of Russell Indexes. This inclusion is expected to enhance company awareness among a broader investor base and improve liquidity. FTSE Russell determines membership through market-capitalization rankings. The Russell Indexes are widely recognized benchmarks for investment managers, with approximately $10.6 trillion in assets linked to them. ProPhase Labs offers clinical diagnostic services, including COVID-19 testing, under its subsidiary ProPhase Diagnostics.

ProPhase Labs (NASDAQ: PRPH) has formed two subsidiaries: ProPhase Precision Medicine focusing on genomics testing, and ProPhase Global Healthcare for international COVID-19 testing. ProPhase Precision Medicine aims to acquire technologies for whole-genome sequencing (WGS), crucial for understanding genetic disorders and drug responses. The drop in WGS costs opens up a multi-billion-dollar genomic diagnostics market. The company also seeks to expand COVID-19 testing internationally, leveraging increased global demand.

ProPhase Labs (NASDAQ: PRPH) announced that CEO Ted Karkus will present at the LD Micro Invitational XI virtual conference on June 10, 2021, at 1:00 p.m. EDT. The conference runs from June 8-10, 2021, and Karkus will discuss the company's diverse medical science and technology initiatives. ProPhase Labs focuses on clinical diagnostics and testing services, particularly in COVID-19 and influenza testing, providing results in under 24 hours. For more details, visit ProPhaseLabs.com.